TEVA

Teva Pharmaceutical (TEVA) P/E Ratio
P/E Ratio as of Oct 29, 2026: 69.14
Average67.20
Median67.19
Minimum65.24
Maximum69.19
69.14
2.77 (4.17%)past month
The P/E ratio for Teva Pharmaceutical (TEVA) is 69.14 as of Oct 29, 2026. This represents a increase of 76.38% compared to its 12-month average P/E ratio of 39.2. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Teva Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Teva Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Teva Pharmaceutical to industry peers.
Teva Pharmaceutical P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Teva Pharmaceutical’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Teva Pharmaceutical to industry peers.
Teva Pharmaceutical (TEVA) P/E Ratio Insights
See Teva Pharmaceutical’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares
Teva Pharmaceutical (TEVA) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Oct 1, 2026 | $39.31 | 65.54 |
| Sep 1, 2026 | $36.19 | 60.85 |
| Aug 3, 2026 | $34.46 | 57.95 |
| Jul 1, 2026 | $33.44 | 24.85 |
| Jun 1, 2026 | $34.64 | 25.74 |
| May 1, 2026 | $34.95 | 25.97 |
| Apr 1, 2026 | $30.25 | 24.85 |
| Mar 2, 2026 | $33.77 | 27.74 |
| Feb 2, 2026 | $35.52 | 29.18 |
| Jan 2, 2026 | $30.95 | 50.55 |
Teva Pharmaceutical (TEVA) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2026 | 69.14 | +35.65% |
| 2025 | 50.97 | -296.72% |
| 2024 | -25.91 | +391.65% |
| 2023 | -5.27 | -32.69% |
| 2022 | -7.83 | -136.99% |
| 2021 | 21.17 | — |
FAQs About Teva Pharmaceutical (TEVA) P/E ratio
The latest P/E ratio of Teva Pharmaceutical (TEVA) is 69.14, as of Oct 29, 2026. This is calculated based on its current stock price and earnings per share (EPS).
Teva Pharmaceutical’s last 12-month average P/E ratio is 39.2, compared to its current P/E ratio of 69.14. This reflects a increase of 76.38%.
Teva Pharmaceutical’s current P/E ratio of 69.14 is higher than its last 12-month average P/E of 39.2. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Teva Pharmaceutical’s average P/E ratio over the last 3 years is -12.27. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Teva Pharmaceutical’s average P/E ratio over the last 5 years is -8.31. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.
Teva Pharmaceutical (TEVA) P/E Ratio Insights
See Teva Pharmaceutical’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.